These two designations should enable TaiGen and/or its partners to benefit from certain incentives for the development of nemonoxacin as a new antibiotic, including an additional five year extension to new chemical entity market exclusivity, priority review, and fast track status provided under the Generating Antibiotic Incentives Now act.
http://www.sys-con.com/node/2907474
http://www.sys-con.com/node/2907474
No comments:
Post a Comment